Short-term ACE inhibition may influence exercise-induced changes in haemostasis in healthy subjects

Fibrinolysis and Proteolysis

Volumn 11, Issue 4, 1997, Pages 187-192

  Frisco, D ^a   Paniccia, R ^a   Bandinelli, B ^a   Giusti, B ^a   Colella, A ^a   Comeglio, M ^a   Abbate, R ^a   Simone, I ^a   Gensini, G F ^a   Neri Serneri, G G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; EXERCISE; EXERCISE TEST; FIBRINOLYSIS; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MALE; PHYSICAL ACTIVITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9844220853     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0268-9499(97)80049-5     Document Type: Article

References (28)

1. Vaughan D E, Shen C, Lazos S A. Angiotensin II induces plasminogen activator inhibitor (PAI-1) in vitro. Circulation 1992; 86 (Suppl I): I-557.
2. Feener E P, Northrup J M, Aiello L P, King G L. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-1362.
3. van Leeuwen R T, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increase plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-368.
4. Ridker P M, Gaboury C L, Conlin P R, Seely E W, Williams G H, Vaughan D E. Stimulation of plasminogen activator inhibitor in vivo by infusion of Angiotensin II. Circulation 1993; 87: 1969-1973.
5. Kerins D M, Qin H, Vaughan D E. Angiotensin induction of PAI1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-2520.
6. Bell L, Madri J A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990; 137:7-12.
7. Bell L, Luthringer D J, Madri A, Warren S L. Automne angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60 expression. J Clin Invest 1992; 89: 315-320.
8. Hamdan A D, Quist W C, Gagne J B, Feener E P. Angiotensinconverting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-1078.
9. Yusuf S, Pepine C J, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178.
10. Pfeffer M A, Braunwald E, Moye AL, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
11. Jansson J H, Boman K, Nilsson T K. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993; 44 : 495-498.
12. Wright R A, Flapan A D, Alberti G M M, Ludlam C A, Fox K A A. Effects of Captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
13. Zehetgruber M, Beckmann R, Gabriel H, Christ G, Bernd R B, Huber K. The ACE-inhibitor lisinopril affects plasma but not fibrinolytic parameters. Thromb Res 1996; 83: 143-152.
14. Bruce R A. Exercise testing of patients with coronary artery disease. Ann Clin Res 1971; 3: 323-332.
15. Chakrabarti R, Bielowiec M, Evans J F, Fearnley G R. Methodological study and recommended technique for determinating the euglobulin lysis time. J Clin Pathol 1968; 21 : 698-704.
16. Rânby M, Norman B, Wallen P A. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 27: 743-749.
17. Korninger C, Speiser W, Woita J, Binder B R. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-535.
18. Chmielewska J, Wiman B. Determination of tissue type plasminogen activator and its 'fast' inhibitor in plasma. Clin Chem 1986; 32: 482-485.
19. Declerck P J, Alessi M C, Verstreken M, Kruithof E K O, JuahanVague I, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71:220-225.
20. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment l +2 in plasma with an antibody against a syntetic peptide. Thromb Haemost 1991 ; 65 : 153-159.
21. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-105.
22. Amiral J, Walenga J M, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemostas 1984; 10: 228-242.
23. Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A. Removal of cross-reactivity fibrinogen with bentonite. Thromb Res 1980; 19: 589-598.
24. Snedecar G W, Cochran W G, eds. Stastical methods. (7th edn). Ames: Iowa State University Press, 1980.
25. Johnston C I, Clappison B H, Anderson W P, Yasujima M. Effect of angiotensin converting enzyme inhibition on circulating and local kinin levels. Am JCardiol 1982; 49: 1401-1404.
26. Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann NY Acad Sei 1992; 667: 249-258.
27. Hamsten A. Hemostatic function and coronary artery disease. N EnglJMed 1995; 332: 677-678.
28. Frisco D, Paniccia R, Guarnaccia V, et al. Thrombin generation after physical exercise. Thromb Res 1993; 69: 159-164.